Noble Financial Keeps 'Buy' Rating on Cynapsus (CYNA) as APL-130277 Receives FDA Fast Track Designation

August 29, 2016 11:54 AM EDT
Get Alerts CYNA Hot Sheet
Price: $40.48 --0%

Rating Summary:
    4 Buy, 0 Hold, 0 Sell

Rating Trend: Up Up

Today's Overall Ratings:
    Up: 1 | Down: 2 | New: 3
Trade CYNA Now!
Join SI Premium – FREE

Get access to the best calls on Wall Street with's Ratings Insider Elite. Get your Free Trial here.

Noble Financial affirms Cynapsus Therapeutics (Nasdaq: CYNA) with a Buy rating and $50 price target after the company announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track Designation for APL-130277, a product candidate for the treatment of OFF episodes in patients with Parkinson’s disease (PD).

Analyst Nathan Cali noted the following on Monday:

  • Importance of Fast Track Designation. Intends to expedite the approval process while granting invaluable access with the FDA; guidance is meant to closely track and aide ongoing clinical trials for a drug, submissions allowed on a rolling basis for FDA review to help ensure trial fluidity for a potential pathway to success; could lead to shorter review time
  • Requirements for Fast Track Validate APL-130277 Clinical Program; obtaining Fast Track requires demonstration of either superior efficacy, avoiding serious side effects, decreasing toxicity or ability to address emerging anticipated public health need
  • Price Target $50; Bullish on upcoming milestones. We estimate that the current cash balance of $55.1 million is sufficient to extend operations near 2018 and potential commercialization of APL-130277; data for APL-130277, Phase III efficacy trial expected in Q4-2016; possible NDA submission to take place in 1H-2017.

For an analyst ratings summary and ratings history on Cynapsus click here. For more ratings news on Cynapsus click here.

Serious News for Serious Traders! Try Premium Free!

You May Also Be Interested In

Related Categories

Analyst Comments, FDA

Related Entities

Noble Financial

Add Your Comment